SENSEX NIFTY
Apr 16, 2012, 01.45 PM IST | Source: Reuters

Piramal buys Bayer's potential Alzheimer drug

Drugmaker Piramal Healthcare has agreed to buy a research and development portfolio from Bayer AG, the company said, in a deal that gives Piramal rights to florbetaben, a possible Alzheimer treatment.

Piramal buys Bayer's potential Alzheimer drug

Drugmaker Piramal Healthcare has agreed to buy a research and development portfolio from Bayer AG, the company said, in a deal that gives Piramal rights to florbetaben, a possible Alzheimer treatment.

Florbetaben, which is in the final stages of clinical trials, works by detecting symptoms in probable sufferers of Alzheimer's, and is expected to allow earlier detection and specific treatment of the disease, Piramal said in a statement.

Florbetaben is racing with similar Alzheimer's imaging agents from global pharmaceutical companies such as Eli Lilly and Co, Pfizer Inc and General Electric Co to enter a global market estimated at anywhere from USD 1 billion to USD 5 billion.

Piramal will acquire intellectual property, worldwide development, marketing and distribution rights of florbetaben and other clinical and pre-clinical assets of Bayer's molecular imaging business in the deal. Financial aspects of the deal were not available.

"We plan to build a promising portfolio in the pharma space, including our newly acquired molecular imaging assets, which will help us create a global branded pharma business," Ajay Piramal, chairman of the Piramal Group, was quoted as saying.

Piramal Enter stock price

On November 21, 2014, Piramal Enterprises closed at Rs 844.60, up Rs 0.05, or 0.01 percent. The 52-week high of the share was Rs 862.05 and the 52-week low was Rs 482.65.


The company's trailing 12-month (TTM) EPS was at Rs 130.67 per share as per the quarter ended September 2014. The stock's price-to-earnings (P/E) ratio was 6.46. The latest book value of the company is Rs 528.91 per share. At current value, the price-to-book value of the company is 1.60.

Set email alert for

ADS BY GOOGLE

video of the day

Be careful while betting on midcaps; like Kotak: Dimensions

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.